ZDA
PACB icon

Zweig-DiMenna Associates’s Pacific Biosciences PACB Stock Holding History

Zweig-DiMenna Associates’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-89,767
Closed -$3.14M – 196
2021
Q2 		$3.14M Buy
+89,767
New +$2.61M 0.19% 122

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Zweig-DiMenna Associates's PACB Position: Q3 2021 in Review

Zweig-DiMenna Associates sold out of Pacific Biosciences (PACB) in Q3 2021, closing a stake of 89,767 shares — an estimated $3.14M sold.

Zweig-DiMenna Associates first reported a position in PACB in Q2 2021 and held it in 1 quarter. The position peaked at $3.14M in Q2 2021. 246 funds tracked by Wall St. Rank hold PACB as of Q3 2021.

  • Zweig-DiMenna Associates reported no remaining Pacific Biosciences position as of Q3 2021 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 89,767 Pacific Biosciences shares in Q3 2021, an estimated $3.14M.
  • Zweig-DiMenna Associates first reported a position in Pacific Biosciences in Q2 2021 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Pacific Biosciences position peaked at $3.14M in Q2 2021.
  • 246 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2021.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2021, filed 25 Oct 2021.